<DOC>
	<DOCNO>NCT03033108</DOCNO>
	<brief_summary>This pharmacodynamics study emixustat hydrochloride subject macular atrophy secondary Stargardt disease .</brief_summary>
	<brief_title>Pharmacodynamic Study Emixustat Hydrochloride Subjects With Macular Atrophy Secondary Stargardt Disease</brief_title>
	<detailed_description>This multicenter , randomize , mask study characterize pharmacodynamics , safety tolerability emixustat subject macular atrophy secondary Stargardt disease .</detailed_description>
	<mesh_term>Atrophy</mesh_term>
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Anetoderma</mesh_term>
	<criteria>Inclusion Criteria , include , limited : Clinical diagnosis macular atrophy ( MA ) secondary Stargardt disease ( STGD ) one eye At least 2 pathogenic mutation ABCA4 gene Early Treatment Diabetic Retinopathy Study BCVA ≥ 20 letter ( approximately ≥ 20/400 Snellen ) study eye Adequate clarity ocular medium adequate pupillary dilation permit good quality image MA study eye Able willing provide write informed consent undergo studyrelated procedure Able reliably administer oral medication self available assistance Exclusion Criteria , include , limited : Macular atrophy associate condition STGD either eye . Presence either eye active ocular disease opinion Investigator compromise confounds visual function . History intraocular ocular surface surgery either eye within 3 month screen . Current previous participation interventional study treat STGD use gene therapy stem cell therapy time , participation interventional study vitamin A derivative ≤3 month prior screen . Prespecified laboratory abnormality screen Presence medical ophthalmic disease , physical examination finding , clinical laboratory find opinion Investigator may contraindicate use investigational drug place subject risk Current history cancer ( except adequately treat basal cell squamous cell carcinoma skin ) within 1 year screen History myocardial infarction , stroke , unstable ischemic heart disease , uncontrolled cardiac arrhythmia , hospitalization congestive heart failure within 6 month screen . Anticipated hospitalization medical/surgical procedure ( ) could result interruption/premature cessation study treatment participation . Electrocardiogram clinically significant abnormal find Female subject pregnant lactate Female subject childbearing potential male subject surgically sterile willing practice medically accept method birth control sexual partner screen 30 day final dose study drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>